Biotech

All Articles

Amgen files first stage 3 win for $400M chronic eczema medication

.Amgen has shared (PDF) the 1st period 3 data on its $400 million eczema medicine, linking the anti-...

Biogen, UCB report period 3 lupus gain after failing earlier trial

.Biogen and UCB's rely on improving in to phase 3 astride a broken research study wants to have actu...

Aptadir wishes brand-new RNA preventions can easily turn around challenging cancers cells

.Italian biotech Aptadir Therapies has actually released along with the pledge that its pipe of prec...

Wave surfs DMD success to regulators' doors, sending stockpile

.Wave Life Sciences has met its own objective in a Duchenne muscular dystrophy (DMD) study, placing ...

Sanofi plucks new CSO from in-stealth biotech

.After a couple of years in biotech, Mike Quigley, Ph.D., is actually going back to the pharma creas...

Achilles drips cell treatment system, braces for layoffs after missing out on 'commercial feasibility' goals

.Achilles Therapeutics has torn up its technique. The British biotech is actually knocking off on it...

Aligos declares phase 2 MASH succeed, lowering liver fat as much as 46%

.Aligos Therapies is actually advertising a midstage gain in metabolic-dysfunction connected steatoh...

Basilea ratings $268M BARDA funding for antifungals, antibiotics

.Basilea Pharmaceutica's work developing brand new antifungals has actually received a substantial i...

Capricor sells Europe rights to late-stage DMD treatment for $35M

.Having presently gathered up the U.S. civil rights to Capricor Therapies' late-stage Duchenne muscu...

FDA fragments adcomm for Applied's rare condition medicine

.After pushing the choice date for Applied Rehabs' metabolic condition drug govorestat, the FDA has ...